HC Wainwright Has Pessimistic Outlook of RVMD Q3 Earnings

Key Points

• HC Wainwright lowered Revolution Medicines’ Q3 2026 EPS estimate to a loss of $2.42 per share from a projected loss of $2.07, while maintaining a Buy rating and $280 price target.
• Revolution Medicines reported a Q2 loss of $3.06 per share, missing the consensus estimate of a $2.04 loss by $1.02. HC Wainwright forecasts a $9.20 per-share loss for fiscal 2026.
• Despite the earnings concerns, analyst sentiment remains favorable, with a consensus Moderate Buy rating and average price target of $198.89. Shares opened at $207.88, near their 52-week high of $224.31, while insiders have sold more than $38 million in stock over the past 90 days.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Revolution Medicines in a research report issued on Thursday, August 27th. HC Wainwright analyst R. Burns now expects that the company will earn ($2.42) per share for the quarter, down from their previous estimate of ($2.07). HC Wainwright has a "Buy" rating and a $280.00 price target on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($8.85) per share. HC Wainwright also issued estimates for Revolution Medicines' Q4 2026 earnings at ($2.23) EPS and FY2026 earnings at ($9.20) EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period last year, the firm earned ($1.31) EPS.

Several other brokerages also recently weighed in on RVMD. Wolfe Research reissued an "outperform" rating and set a $220.00 price target on shares of Revolution Medicines in a research report on Monday, August 10th. Piper Sandler upped their price objective on Revolution Medicines to $172.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. Needham & Company LLC increased their target price on Revolution Medicines from $236.00 to $240.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Oppenheimer lifted their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, UBS Group boosted their price target on Revolution Medicines from $220.00 to $265.00 and gave the stock a "buy" rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $198.89.

Revolution Medicines Stock Performance

Shares of NASDAQ RVMD opened at $207.88 on Monday. The firm's 50 day moving average price is $193.33 and its 200-day moving average price is $148.95. Revolution Medicines has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The company has a market cap of $44.56 billion, a PE ratio of -23.57 and a beta of 1.39.

Insider Buying and Selling

In other Revolution Medicines news, Director Sushil Patel sold 5,580 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director owned 21,656 shares of the company's stock, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Margaret A. Horn sold 29,600 shares of the firm's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total value of $4,739,552.00. Following the completion of the transaction, the chief operating officer directly owned 154,647 shares in the company, valued at $24,762,077.64. The trade was a 16.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 212,497 shares of company stock valued at $38,206,486 over the last ninety days. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors have recently made changes to their positions in RVMD. California State Teachers Retirement System boosted its holdings in shares of Revolution Medicines by 26,920.9% in the second quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company's stock worth $8,363,803,000 after buying an additional 44,494,074 shares during the last quarter. Janus Henderson Group PLC grew its position in Revolution Medicines by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company's stock valued at $980,036,000 after buying an additional 947,448 shares during the period. Nextech Invest Ltd. increased its holdings in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Paradigm Biocapital Advisors LP increased its holdings in Revolution Medicines by 6.8% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company's stock valued at $529,227,000 after buying an additional 421,112 shares during the last quarter. Finally, Bellevue Group AG raised its position in Revolution Medicines by 21.7% in the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company's stock worth $260,298,000 after acquiring an additional 994,538 shares during the period. Institutional investors own 94.34% of the company's stock.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source